Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
DUBLIN, Ireland and TREVOSE, Pa., Jan. 04, 2017 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the 9th Annual Biotech Showcase™ taking place January 9 –11, 2017 at the Hilton San Francisco Union Square in San Francisco, California.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Monday, January 9, 2017, at 10:30 a.m. Pacific Time. The presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations The Trout Group Marcy Nanus +1 646-378-2927 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
